EIF4A2 and lymphoma: Here, we examine the effect of a synthetic eIF4A inhibitor (CR-1-31 B) against aggressive, MYC and BCL2 positive lymphomas and we specifically explore potential mechanisms of resistance to the eIF4A inhibitor treatment.